secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001619856-23-000123
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Biosciences Q3 net loss $10M, cash $396.7M; pipeline advances with CB-010, CB-011, CB-012
--------------------------------------------------------------------------------

- Net loss of $10.0M for Q3 2023 vs $26.6M in Q3 2022; revenue $23.7M (incl. $21.5M from AbbVie termination).
- Cash, equivalents, and marketable securities $396.7M as of Sept 30, 2023; funding expected into Q4 2025.
- CB-010 ANTLER trial dose expansion continues; FDA meeting for pivotal trial planned, data H1 2024.
- CB-011 CaMMouflage trial at dose level 2; CB-012 IND cleared, enrollment expected by mid-2024.
- Completed $134.4M follow-on offering and received $25M Pfizer investment in Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000123/0001619856-23-000123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000123/crbu-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer